In this episode, we dive into the major shift happening in the U.S. diabetes tech industry: insulin pumps are moving from Durable Medical Equipment (DME) to pharmacy benefits, offering easier access, lower costs, and more flexibility for users. I’m joined by Jeff DelVerne, author of The Healthcare Economy Substack and Director of Payer Relations at Beta Bionics, to break down what this transition means for people with diabetes. We discuss how moving pumps to pharmacy benefits could encourage faster innovation and give users more freedom to switch devices — while also examining potential challenges, like the risk of insurers introducing tiered pump coverage similar to drug formularies.

Learn about Omnipod 5 (today's sponsor)*

T1D Exchange Registry Sign up  (US residents only)

Watch This Episode On Youtube

Join our Newsletter | Support us on Patreon 

Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook

DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care. 

*10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.